This week, we say Auf wiedersehen to Vienna and move on to the North west. Leuven, the capital city of the Flemish Brabant province in Belgium, fairly close to the country’s capital Brussels. And it is also where ThromboGenics, our Biotech of The Week is located.
City: Leuven (Belgium)
Employees: 85 (including US)
Market cap: €117.9M (on 13/04/2016)
CEO: Patrik De Haes
Mission: Aiming to help patients worldwide, ThromboGenics, founded in 1998, develops novelty and better treatments for several eye conditions. Their main focus is the development of therapies that meets clinical needs in Ophthalmology.
However, they also expanded their research and development range to cardiovascular and oncology programs. They have been listed on the NYSE Euronext Brussels stock exchange since 2006.